StoneX Group’s Traws Pharma TRAW Stock Holding History

StoneX Group’s Portfolio TRAW Stock Details TRAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-523	Closed	-$8.44K	–	706
2022 Q4	$8.44K	Sell	523 -77	-13%	-$1.45K	﹤0.01%	459
2022 Q3	$13.2K	Hold	600	–	–	﹤0.01%	294
2022 Q2	$19.8K	Buy	+600	New	+$20.2K	﹤0.01%	436

Other funds holding TRAW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

HWA

Hillcrest Wealth Advisors Hazlet, New Jersey $279M AUM 21.72% 1-Year Est. Return

StoneX Group's TRAW Position: Q1 2023 in Review

StoneX Group sold out of Traws Pharma (TRAW) in Q1 2023, closing a stake of 523 shares — an estimated $8.44K sold.

StoneX Group first reported a position in TRAW in Q2 2022 and held it in 3 quarters. The position peaked at $19.8K in Q2 2022. 24 funds tracked by Wall St. Rank hold TRAW as of Q1 2023.

StoneX Group reported no remaining Traws Pharma position as of Q1 2023 after selling out during the quarter.
StoneX Group sold 523 Traws Pharma shares in Q1 2023, an estimated $8.44K.
StoneX Group first reported a position in Traws Pharma in Q2 2022 and held it in 3 quarters.
StoneX Group's Traws Pharma position peaked at $19.8K in Q2 2022.
24 funds tracked by Wall St. Rank held Traws Pharma as of Q1 2023.

Based on StoneX Group's 13F filing for Q1 2023, filed 11 May 2023.